Economic evaluation and the postponement of health care costs

Health Economics

Volumn 20, Issue 4, 2011, Pages 432-445

  Van Baal, Pieter H M ^a,b   Feenstra, Talitha L ^a,c   Polder, Johan J ^a,d   Hoogenveen, Rudolf T ^a   Brouwer, Werner B F ^b  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d TILBURG UNIVERSITY   (Netherlands)

Author keywords

Cost effectiveness analysis; Economic evaluation; Medical costs in life years gained; Modeling

Indexed keywords

AGE; CHRONIC DISEASE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; ECONOMIC EVALUATION; HEALTH CARE COST; HUMAN; LIFESPAN; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; SMOKING CESSATION;

COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; LIFE EXPECTANCY; MODELS, ECONOMETRIC; QUALITY-ADJUSTED LIFE YEARS; SMOKING CESSATION; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 79952579749     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1599     Document Type: Review

References (35)

1. Claxton K, Sculpher M, Culyer A, McCabe C, Briggs A, Akehurst R, Buxton M, Brazier J. 2006. Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion. Health Economics 15: 1-4. (Pubitemid 43141521)
2. CVZ. 2005. Richtlijnen voor farmaco-economisch onderzoek: evaluatie en actualisatie (Guidelines for pharmacoeconomic research). College voor zorgverzekeringen, Amstelveen.
3. Feenstra TL, Hamberg-van Reenen HH, Hoogenveen RT, Rutten-van Molken MP. 2005. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. Value in Health 8: 178-190. (Pubitemid 41023477)
4. Feenstra TL, van Baal PH, Gandjour A, Brouwer WB. 2008. Future costs in economic evaluation. A comment on Lee. Journal of Health Economics 27: 1645-1649; discussion 1650-1651.
5. Feenstra TL, van Genugten ML, Hoogenveen RT, Wouters EF, Rutten-van Molken MP. 2001. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. American Journal of Respiratory and Critical Care Medicine 164: 590-596. (Pubitemid 32801662)
6. Gandjour A, Lauterbach KW. 2005. Does prevention save costs? Considering deferral of the expensive last year of life. Journal of Health Economics 24: 715-724. (Pubitemid 40800155)
7. Garber AM, Phelps CE. 1997. Economic foundations of cost-effectiveness analysis. Journal of Health Economics 16: 1-31. (Pubitemid 27224092)
8. Godfrey C, Parrott S, Coleman T, Pound E. 2005. The cost-effectiveness of the English smoking treatment services: evidence from practice. Addiction 100(Suppl 2): 70-83. (Pubitemid 40525072)
9. Gold MR, Siegel JE, Russell LB, Weinstein MC (ed.). 1996. Cost-effectiveness in Health and Medicine. Oxford University Press: New York, 0-19-510824-8.
10. Hakkinen U, Martikainen P, Noro A, Nihtila E, Peltola M. 2008. Aging, health expenditure, proximity to death, and income in Finland. Health Economics, Policy and Law 3: 165-195. (Pubitemid 351493996)
11. Hoogenveen RT, van Baal PH, Boshuizen HC, Feenstra TL. 2008. Dynamic effects of smoking cessation on disease incidence, mortality and quality of life: the role of time since cessation. Cost Effectiveness and Resource Allocation 6: 1.
12. Hoogenveen RT, van Baal PHM, Boshuizen HC. 2010. Chronic disease projections in heterogeneous ageing populations: approximating multi-state models of joint distributions by modelling marginal distributions. Mathematical Medicine and Biology 27: 1-19. DOI: 10.1093/imammb/dqp014. Mathematical Medicine and Biology Advance Access Published on 10 June 2009.
13. Jacobs-van der Bruggen MA, Bos G, Bemelmans WJ, Hoogenveen RT, Vijgen SM, Baan CA. 2007. Lifestyle interventions are cost-effective in people with different levels of diabetes risk: results from a modeling study. Diabetes Care 30: 128-134. (Pubitemid 46052510)
14. Lee RH. 2008. Future costs in cost effectiveness analysis. Journal of Health Economics 27: 809-818.
15. Meltzer D. 1997. Accounting for future costs in medical cost-effectiveness analysis. Journal of Health Economics 16: 33-64. (Pubitemid 27224093)
16. Meltzer D. 2008. Response to 'Future costs and the future of cost-effectiveness analysis'. Journal of Health Economics 27: 822-825.
17. Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R. 2006. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20 536 people. British Medical Journal 333: 1145.
18. NICE. 2008. Guide to the methods of technology appraisal. National Institute for Health and Clinical Excellence: London [online]. Available from URL: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf [Accessed 17 July 2008].
19. Nyman JA. 2004. Should the consumption of survivors be included as a cost in cost-utility analysis? Health Economics 13: 417-427.
20. Polder JJ, Barendregt JJ, van Oers H. 2006. Health care costs in the last year of life - the Dutch experience. Social Science and Medicine 63: 1720-1731. (Pubitemid 44176177)
21. Rappange DR, van Baal PH, van Exel NJ, Feenstra TL, Rutten FF, Brouwer WB. 2008. Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions? Pharmacoeconomics 26: 815-830.
22. Russell LB (ed.). 1986. Is Prevention Better Than Cure? Brookings Institution: Washington, 0-19-510824-8.
23. Seshamani M, Gray A. 2004a. Ageing and health-care expenditure: the red herring argument revisited. Health Economics 13: 303-314. (Pubitemid 38477075)
24. Seshamani M, Gray A. 2004b. Time to death and health expenditure: an improved model for the impact of demographic change on health care costs. Age and Ageing 33: 556-561. (Pubitemid 39504286)
25. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. 2002. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews CD000146.
26. Slobbe LCJ, Kommer GJ, Smit JM, Groen J, Meerding WJ, Polder JJ. 2006. Costs of illness in the Netherlands 2003. RIVM Report 270751010, Rijksinstituut voor Volksgezondheid en Milieu.
27. Spillman BC, Lubitz J. 2000. The effect of longevity on spending for acute and long-term care. New England Journal of Medicine 342: 1409-1415. (Pubitemid 30262399)
28. Statistics Netherlands. Statline [www.cbs.nl]. Available from: http://www.cbs.nl/en/figures/statline. 2006.
29. Struijs JN, van Genugten ML, Evers SM, Ament AJ, Baan CA, van den Bos GA. 2005. Modeling the future burden of stroke in The Netherlands: impact of aging, smoking, and hypertension. Stroke 36: 1648-1655. (Pubitemid 41098756)
30. van Baal PH, Brouwer WB, Hoogenveen RT, Feenstra TL. 2007a. Increasing tobacco taxes: a cheap tool to increase public health. Health Policy 82: 142-152. (Pubitemid 46779138)
31. van Baal PH, Feenstra TL, Hoogenveen RT, deWit GA, Brouwer WB. 2007b. Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a 'perfect' cost-utility ratio. Health Economics 16: 421-433.
32. van Baal PH, Hoogenveen RT, de Wit GA, Boshuizen HC. 2006. Estimating health-adjusted life expectancy conditional on risk factors: results for smoking and obesity. Population Health Metrics 4: 14.
33. van Baal PH, Polder JJ, de Wit GA, Hoogenveen RT, Feenstra TL, Boshuizen HC, Engelfriet PM, Brouwer WB. 2008. Lifetime medical costs of obesity: prevention no cure for increasing health expenditure. PLoS Medicine 5: e29.
34. Weinstein MC, Manning Jr WG. 1997. Theoretical issues in cost-effectiveness analysis. Journal of Health Economics 16: 121-128.
35. Zweifel P, Felder S, Meiers M. 1999. Ageing of population and health care expenditure: a red herring? Health Economics 8: 485-496.